Clinical Trial Search

Primary: Maximum Percent Fall in FEV1 After Exercise Challenge at 2 Hours Post-dose Compared With Pre-exercise Baseline in Patients With Exercise-induced Bronchospasm (EIB)…

Primary: Change From Baseline to Week 8 in the MADRS (Montgomery-Asberg Depression Rating Scale) Total Score. — -13.3; -10.8 Units on a scale — p=0.009

Primary: Hemagglutination Inhibition (HI) Antibody Titer — 10.2; 8.7; 314.1; 89.4 titer

Primary: Reduction in Primary Joint Contracture to 5° or Less — 44.4; 4.8 Percentage of Joints — p=<.001

Primary: Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection — 64; 6.8 Percentage of Joints — p=<0.001

Primary: Reduction in Contracture to 5° or Less — 41.9 Percentage of joints

Primary: Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision) — 644.50; 677.50 Days — p=0.612

Primary: Reduction in Contracture to 5° or Less — 52.7 percentage of joints

Primary: Participants With Markedly Abnormal Change in Vital Signs and Body Weight — 9; 4; 3; 3 participants

Primary: Change From Baseline in Human Immunodeficiency Virus (HIV-1) Viral Load (Ribonucleic Acid [RNA]) — -0.890; -1.194; -0.953; -0.604 log10 copies/mL

Primary: Ischemia Driven Target Lesion Failure (TLF) — 4.2; 6.8 Percentage of participants

Primary: Number of Subjects With at Least One Adverse Event During the Treatment Period (up to 7 Days) — 17; 42; 20 subjects

Primary: Presence of Agitation and/or Psychosis Measured by the Neuropsychiatric Inventory (NPI) Combined With an Assessment of the Clinical Significance of Behavioral Change…

Primary: Dental Plaque — 2.273; 1.806; 2.041 Units on a scale — p=<0.05

Primary: Number of Viral Load (VL) < 50 HIV-1 RNA Copies/mL (Time to Loss of Virologic Response[TLOVR]) Subjects by Sex — 146; 83 participants — p=0.30